← Leaderboards
David J Farabee
University Of California Los Angeles
$9,964,334
Attributed
$28,001,080
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $17.8M · FY2005–24$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$28,001,080 · 6
By mechanism
U01$22,642,261 · 2
R01$4,398,664 · 2
R42$860,241 · 1
R41$99,914 · 1
Top collaborators
- Thomas J Stopka3 shared
- Peter D. Friedmann2 shared
- Jan Gryczynski2 shared
- Joshua D Lee2 shared
- Lisa A Marsch2 shared
- Sandra Ann Springer2 shared
- Elizabeth Needham Waddell2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Adeline M Nyamathi$17,618,463
- Chelsea Leigh Shover$2,070,879
- Walter Nmn Ling$59,224,910
- Elizabeth Barnert$1,475,126
- Nina Thawata Harawa$9,726,081
Others in their field
Top investigators on “Randomized”
- James Dennis Neaton · Northwestern University$305,243,252
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$292,521,996
- Lawrence Corey · Fred Hutchinson Cancer Center$292,521,996
- Marian Ewell · The Emmes Company, Llc$278,931,253
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$199,647,509
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
Research focus
RandomizedRelapsePharmaceutical PreparationsResearch PersonnelCommunitiesPatient Self-ReportParticipantFollow-UpCriminal JusticeDrug UsageSamplingProtocols DocumentationAdultJailMedicalDrug AbuseProgramsCountyOpioidCostEffectivenessBuprenorphineImprisonmentTelephone
Grant awards (18)
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$2,498,125
U01 · FY2024 · DA
Assessing Optimal XR-Buprenorphine Initiation Points in Jail$622,971
R01 · FY2024 · DA · contact PI
Assessing Optimal XR-Buprenorphine Initiation Points in Jail$606,093
R01 · FY2023 · DA · contact PI
Assessing Optimal XR-Buprenorphine Initiation Points in Jail$657,049
R01 · FY2022 · DA · contact PI
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$17,761,674
U01 · FY2019 · DA
Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs$537,602
U01 · FY2016 · DA · contact PI
Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs$650,755
U01 · FY2015 · DA · contact PI
Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs$598,319
U01 · FY2014 · DA · contact PI
Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs$526,172
U01 · FY2013 · DA · contact PI
Enhancing Follow-up Rates through a Rechargable Incentive Card (RIC) System$259,015
R42 · FY2013 · DA · contact PI
Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs$69,614
U01 · FY2013 · DA · contact PI
Enhancing Follow-up Rates through a Rechargable Incentive Card (RIC) System$601,226
R42 · FY2012 · DA · contact PI
Four Models of Telephone Support for Stimulant Recovery$491,804
R01 · FY2009 · DA · contact PI
Enhancing follow-up rates through a Rechargable Incentive Card (RIC) System$99,914
R41 · FY2009 · DA · contact PI
Four Models of Telephone Support for Stimulant Recovery$500,354
R01 · FY2008 · DA · contact PI
Four Models of Telephone Support for Stimulant Recovery$498,174
R01 · FY2007 · DA · contact PI
Four Models of Telephone Support for Stimulant Recovery$512,269
R01 · FY2006 · DA · contact PI
Four Models of Telephone Support for Stimulant Recovery$509,950
R01 · FY2005 · DA